Intended for healthcare professionals

Rapid response to:

Editorials

Chloroquine and hydroxychloroquine in covid-19

BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1432 (Published 08 April 2020) Cite this as: BMJ 2020;369:m1432

Read our latest coverage of the coronavirus outbreak

Rapid Response:

Re: My previous response (Trial of ivermectin for treatment and prophylaxis of COVID-19) in response to Chloroquine and hydroxychloroquine in covid-19

Dear Editor

Clarification:

We regret any inference that the intended dose of Ivermectin in potential controlled trials of post-exposure prophylaxis for COVI-19 should try to emulate the high concentrations that were virocidal in the in-vitro studies. Our intent was to promote consideration of Ivermectin doses known to be easily and safely administered, such as used for scabies treatment or control. This was clearly stated in an earlier response we wrote on the same topic (https://www.bmj.com/content/369/bmj.m1432/rr-26). We hope that no harm has been done by misguided administrations caused by our communication.

Best regards

Competing interests: No competing interests

28 May 2020
Wendy E Hoy
Professor/Physician /Nephrologist/Population health researcher
The University of Queensland
Centre for Chronic Disease, SoCM, Faculty of Medicine, The University of Queensland